An announcement from Haleon PLC ( (GB:HLN) ) is now available.
Haleon PLC announced the purchase of 821,144 ordinary shares for cancellation as part of its share buyback program. This transaction is part of Haleon’s strategy to manage its share capital and potentially enhance shareholder value. The company’s registered share capital now stands at 9,034,845,270 ordinary shares, with 9,030,765,065 shares having voting rights. This move reflects Haleon’s ongoing efforts to optimize its financial structure and could have implications for its market positioning and shareholder engagement.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health through its diverse product portfolio. The company operates in five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements. Haleon is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are built on a foundation of science, innovation, and deep human understanding.
YTD Price Performance: 1.62%
Average Trading Volume: 28,494,085
Technical Sentiment Signal: Sell
Current Market Cap: £34.63B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.